Impressum Bookmark Kontakt Sitemap

Hämoblastosen - B- und T-Zell-Lymphome (NHL) -
Indolente (reife) B- und T-Zell-Lymphome - Weiterführende Informationen

Indolente (reife) B- und T-Zell-Lymphome

Leitlinien

 

DGHO → Leitlinien (02/2010)

 

Studien

 

www.lymphome.de; www.studien.de (national); www.clinicaltrials.gov (international-USA)

 

Literatur

 

  1. Buske C et al: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphplasmacytic lymphoma. results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009; 23: 153-161
  2. Dreyling M: Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (suppl): 181–3
  3. Evens AM et al: A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008; 140: 385–93
  4. Friedberg JW et al: The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807–12
  5. Habermann TM et al: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009; 145: 344–49
  6. Hagenbeek A: Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol 2009; 27: 1540–42
  7. Hagenbeek A et al: First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase I/II trial. Blood 2008; 111: 5486–95
  8. Hess G et al: Phase III study to evaluate temsirolimus compared with investigator`s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 382–9
  9. Hochster H et al: Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG 1496 study. J Clin Oncol 2009; 27: 1607–14
  10. Hoster E et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–65
  11. Khouri IF et al: Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–36
  12. Kluin-Nelemans H: Rituximab maintenance doubles remission duration in MCL. EHA 10.6.2011
  13. Leonard J et al: Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter phase II study in recurrent indolent non-Hodgkin’s lymphoma. Cancer 2008; 113: 2714–23
  14. Marcus R et al: Phase III study of R-CVP compared with cyclophosphamide, vincristine and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579–86
  15. Morschhauser F et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first line remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156–64
  16. O`Connor OA et al: Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicenter phase II clinical trial: Br J Haematol 2009; 145: 34–39
  17. Robinson KS et al: Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin`s lymphoma. J Clin Oncol 2008; 26: 4473–79
  18. Rummel MJ et al: Bendamustin plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114: 168 (#405)
  19. Sacci S et al: Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients wit recurrent follicular lymphoma. Cancer 2007; 110: 121–8
  20. Schuster S et al.: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 2009; 27: #2
  21. Van Oers MHJ et al: Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin`s lymphoma: long trem outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28: 2853-58
  22. Vidal L et al: Rituximab as maintenance for the treatment of patients with follicular lymphoma. J Natl Cancer Inst 2009; 101: 248–55
  23. Wang M et al: Phase II trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cyarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 2008; 113: 2734–42
  24. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES,Pileri SA, Stein H, Thiele J, Vardiman JW et al (eds). International Agency of Research on Cancer (IARC), 4th Edition, Lyon 2008
  25. Zhou H et al: Rituximab maintenance therapy for follicular lymphoma: Lancet 2011; 377: 1150–1